Loading organizations...
C-Bridge Capital, known as CBC Group, operates as Asia's preeminent healthcare-dedicated asset management firm. It focuses on private investments across the healthcare and biotechnology sectors. Utilizing an "investor-operator" approach, the firm strategically deploys capital into pharmaceuticals, biotechnology, medical technology, and healthcare services, fostering innovation and active engagement.
Founded in 2014, the firm was established by Jimmy Wei, its Founder and Managing Partner. Wei recognized the critical need within the rapidly expanding Asian healthcare market for an investment firm combining substantial capital with deep operational expertise. This foundational insight shaped C-Bridge Capital’s distinctive approach to empowering industry growth.
C-Bridge Capital supports leading healthcare companies, providing strategic funding and operational guidance. Its long-term vision aims to significantly advance the global healthcare landscape. By identifying and nurturing high-potential assets through its active model, C-Bridge Capital seeks to drive sustainable growth and impactful innovation across the industry.
Key people at C-Bridge Capital.
C-Bridge Capital was founded in 2014 by Wei Fu (Founder & Chief Executive Officer).
C-Bridge Capital was founded in 2014 by Wei Fu (Founder & Chief Executive Officer).
Key people at C-Bridge Capital.
C-Bridge Capital has 6 tracked investments across 6 companies. The latest tracked deal is $3.7M Series A Extension in 3DC in June 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 6, 2024 | 3DC | $3.7M Series A Extension | — | Yuta Motoshima, Tomohiro Otsuki, Mitsubishi UFJ Capital, Junya Yasuda, Kazuto Hatano, Takasago Industry |
| Nov 16, 2023 | Rutilea | $4.0M Series C | Abies Ventures | Last ONE Mile, Monozukuri Ventures, Shimadzu Future Innovation Fund, Star Mica Holdings, Wingarc 1ST |
| Jun 29, 2018 | I-Mab Biopharma | $220.0M Mab Biopharma - Series C | Hony Capital | Ally Bridge Group, CDH Investments, EDBI, Hillhouse Capital, Hopu Investments |
| May 8, 2018 | BorderX Lab | $20.0M Series B | Eric Feng | Hillhouse Capital Group, HAN Shen, Welight Capital |
| Apr 2, 2018 | CMAB BioPharm | $34.0M Series B | — | Cormorant Asset Management, Tigermed |
| Jan 3, 2017 | Ascletis | $100.6M Series B | C Bridge Capital | FOCUS Media Jiangnanchun Foundation, Goldman Sachs, Tasly Pharmaceutical, WTT Investment |
